Caboxib (Cabozantinib) 20mg/80mg | Multi-Kinase Inhibitor | Ziska Pharmaceuticals Ltd. | GLT

REQUEST A QUOTE

For individuals and institutions — pricing, availability, and product documents (COA) provided within 24 hours.
Direct line: [email protected] · +86 15234153837

分享
Product description

Caboxib is a generic cabozantinib manufactured by Ziska Pharmaceuticals in Bangladesh. This listing offers both standard capsule strengths — 20 mg in packs of 90 and 80 mg in packs of 30 — covering the complete range needed for the two principal dosing regimens of this multi-kinase inhibitor.

Generic Information: Caboxib (Cabozantinib)

Ziska Pharmaceuticals Ltd. is an established Bangladeshi manufacturer with a growing oncology portfolio and regional export reach. Caboxib is its cabozantinib brand, containing the same active ingredient as the originator Cometriq and Cabometyx. The availability of both the 20 mg and 80 mg strengths in one listing makes it convenient for clinics managing different indications.

What Is Caboxib (Cabozantinib) Used For?

Caboxib is used to treat medullary thyroid cancer, renal cell carcinoma, hepatocellular carcinoma, differentiated thyroid cancer and neuroendocrine tumors. The 20 mg and 80 mg capsules are combined to reach the dose appropriate for each condition.

How Does Caboxib Work?

Cabozantinib inhibits several receptor tyrosine kinases — chiefly MET, VEGFR-2 and RET, along with AXL, KIT and FLT-3. This multi-target action suppresses tumor proliferation, starves tumors of new blood vessels and limits metastasis. Caboxib delivers the same mechanism as the originator.

Indications

  • Progressive, metastatic medullary thyroid cancer
  • Advanced renal cell carcinoma
  • Hepatocellular carcinoma after sorafenib
  • Differentiated thyroid cancer refractory to radioactive iodine
  • Well-differentiated neuroendocrine tumors

Dosage & Administration

For medullary thyroid cancer, the dose is 140 mg once daily, made up from 80 mg and 20 mg capsules. For renal cell carcinoma, hepatocellular carcinoma, differentiated thyroid cancer and neuroendocrine tumors, the dose is 60 mg once daily. Both strengths in this listing support these regimens. Swallow capsules whole.

Side Effects

Diarrhea, fatigue, nausea, decreased appetite, hand-foot skin reaction and hypertension are common. Serious risks include severe bleeding, gastrointestinal perforation, blood clots, heart problems and osteonecrosis of the jaw. Monitoring of blood pressure and liver function is required.

Storage & Handling

Store at room temperature in the original packaging, protected from moisture and light, out of children's reach, and not past expiry.

Why Choose Caboxib?

  • Both strengths available — 20 mg and 80 mg in one listing.
  • Ziska Pharmaceuticals — an established Bangladeshi oncology manufacturer.
  • Affordable — lower-cost cabozantinib for multiple cancer indications.

How to Order Caboxib from GLT

  1. Contact GLT via WhatsApp +86 15234153837 or email [email protected].
  2. Receive a quotation and delivery estimate.
  3. Pay via Hao Yi Lian / 好易联.
  4. Dispatch with documentation and tracking.

A valid prescription may be requested before dispatch. Institutions and individual patients are served.

FAQ

1. What strengths does Caboxib come in?

Caboxib is available as 20 mg and 80 mg capsules in this listing.

2. Who manufactures Caboxib?

Caboxib is manufactured by Ziska Pharmaceuticals Ltd. in Bangladesh.

3. Do I need a prescription?

Yes, cabozantinib is prescription-only.

Related Oncology Products

Palutini(巴瑞替尼)4mg | 仿制 JAK1/JAK2 抑制剂 | Trans Continental Life Science & Pharmaceuticals (TLPH) | GLT

由 Trans Continental Life Science & Pharmaceuticals (TLPH)(老挝)生产的仿制巴瑞替尼(JAK1/JAK2 抑制剂)——用于类风湿关节炎、特应性皮炎和斑秃,是 Olumiant 的平价替代品。

Baricent(巴瑞替尼)2mg | 仿制 JAK1/JAK2 抑制剂 | Incepta Pharmaceuticals Ltd. | GLT

由 Incepta Pharmaceuticals Ltd.(孟加拉国)生产的仿制巴瑞替尼(JAK1/JAK2 抑制剂)——用于类风湿关节炎、特应性皮炎和斑秃,是 Olumiant 的平价替代品。

欣可平 XinKePing(阿伐曲泊帕)20mg*10片 | 南京恒生制药 | GLT

欣可平——南京恒生制药(济民可信集团)马来酸阿伐曲泊帕片,原料药与制剂一体化生产,中国大陆

奥氟格列隆/奥格列龙(LuciOrfor)0.8–17.2mg 片剂 | 老挝仿制药 口服 GLP-1 | GLT

卢修斯制药(老挝)有限公司出品奥氟格列隆(奥格列龙)仿制药,6 档剂量递增方案,用于体重管理

奥氟格列隆/奥格列龙(OriYo)0.8–17.2mg 片剂 | 孟加拉仿制药 口服 GLP-1 | GLT

孟加拉国民制药(National Drug Co.)仿制奥氟格列隆,6 剂量递增用于体重管理

Barinib(巴瑞替尼)2mg | 仿制 JAK1/JAK2 抑制剂 | Drug International Limited | GLT

由 Drug International Limited(孟加拉国)生产的仿制巴瑞替尼(JAK1/JAK2 抑制剂)——用于类风湿关节炎、特应性皮炎和斑秃,是 Olumiant 的平价替代品。

Mounjaro KwikPen(替尔泊肽)10–60mg/2.4mL 多剂量注射笔 | 礼来(美国)| GLT

Mounjaro KwikPen——礼来单患者多剂量注射笔,六种美国规格(10–60mg/2.4mL,各 4 剂)用于 2 型糖尿病。